Inspire Medical Systems, Inc. (INSP) Stock Price & Analysis
Inspire Medical Systems, Inc. (INSP) fell 3.19% to USD 49.19 as of July 25, 2026 at 15:42 UTC, according to Nexqual real-time market data.
INSP last closed at USD 50.81; the session ranged USD 49.19–52.01 on volume of 513,577 shares. Market capitalization is $1.42B, with a 52-week range of USD 38.91–147.03 (NYQ). Source: Nexqual, July 25, 2026 at 15:42 UTC.
Key Statistics (as of July 25, 2026 at 15:42 UTC)
| Price | USD 49.19 |
|---|---|
| Change | ▼ 3.19% (down) |
| Previous Close | USD 50.81 |
| Open | USD 51.57 |
| Day Range | USD 49.19 – 52.01 |
| 52-Week Range | USD 38.91 – 147.03 |
| Volume | 513,577 shares |
| Market Cap | $1.42B |
| Exchange | NYQ |
Technical Analysis (INSP)
Nexqual's technical model rates INSP "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:42 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.63 (neutral) |
| vs SMA50 | Above (USD 45.05) |
| MACD | 1.64 (positive) |
Analyst Ratings (INSP)
Wall Street analysts rate INSP "Hold" based on 13 analysts, with a mean price target of USD 52.38 (range USD 39–65), per Nexqual as of July 25, 2026 at 15:42 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 52.38 |
| High Target | USD 65 |
| Low Target | USD 39 |
| Buy / Hold / Sell | 3 / 12 / 1 |
Earnings (INSP)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $194.64M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.1 vs est -0.26 ▲ beat |
| 2025-12-31 | USD 1.65 vs est 0.68 ▲ beat |
| 2025-09-30 | USD 0.38 vs est -0.17 ▲ beat |
| 2025-06-30 | USD 0.45 vs est 0.2 ▲ beat |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financials & Fundamentals (INSP)
| Total Revenue | $915.25M |
|---|---|
| Revenue Growth (YoY) | +1.60% |
| Gross Margin | +85.78% |
| Operating Margin | -0.55% |
| Profit Margin | +14.33% |
| ROE | +18.37% |
| Debt / Equity | 3.73 |
| Current Ratio | 6.34 |
| Total Cash | $283.83M |
| Total Debt | $29.55M |
| Free Cash Flow | $85.58M |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financial Health Score (INSP)
Nexqual rates Inspire Medical Systems, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 15:42 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 86%, operating -1% |
| Balance Sheet | Strong — $284M cash vs $30M debt, net cash position |
| Cash Flow | Solid — FCF $86M, 9% margin |
| Efficiency | Solid — ROE 18%, ROA 3.9% |
Ownership (INSP)
| Insider Ownership | +1.15% |
|---|---|
| Institutional Ownership | +123.02% |
| Shares Outstanding | 28.81M |
| Float | 25.46M |
| Short % of Float | +19.76% |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Leadership (INSP)
Inspire Medical Systems, Inc. is led by Timothy P. Herbert (age 62), Founder, Chairman, CEO & President, per Nexqual as of July 25, 2026 at 15:42 UTC.
| Founder, Chairman, CEO & President | Timothy P. Herbert (age 62) |
|---|---|
| Chief Strategy and Growth Officer | Carlton W. Weatherby (age 40) |
| Executive VP & CFO | Matthew J. Osberg (age 48) |
| Vice President of Investor Relations | Ezgi Yagci |
| Chief Product & Innovation Officer | John C. Rondoni (age 45) |
Major Backers & Investors (INSP)
Notable institutional backers of Inspire Medical Systems, Inc. include Deerfield Management Company, L.P, Wellington Management, Morgan Stanley, according to Nexqual as of July 25, 2026 at 15:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 9.38% |
| Wellington Management | 8.8% |
| Morgan Stanley | 5.03% |
| Shaw D.E. & Co., Inc. | 4.12% |
| William Blair Investment Management, LLC | 3.95% |
| Assenagon Asset Management S.A. | 3% |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 25.13% |
| BlackRock | 18.59% |
| State Street | 4.15% |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
From Inspire Medical Systems, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA.
- Our Solution for OSA Overview of Inspire Therapy Our proprietary Inspire system is the first FDA-approved closed-loop neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
- Our proprietary algorithm tracks breathing patterns and the neurostimulator delivers electrical stimulation at the start of inspiration.
- We have developed the first FDA-approved neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA who have been confirmed to fail or cannot tolerate PAP treatments, such as CPAP.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INKT | MiNK Therapeutics, Inc. | USD 11.07 | ▲ 8.11% |
| CNET | ZW Data Action Technologies Inc | USD 0.79 | ▼ 17.4% |
| VRSN | VeriSign, Inc. | USD 280 | ▲ 6.63% |
| CMRC | Commerce.com, Inc. - Series 1 | USD 2.71 | ▼ 0.37% |
| ATHM | Autohome Inc. | USD 21.11 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:42 UTC. This page is informational and not investment advice.